Habib J Dable
CIK 1690773 · CEO and President · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
10
Total Filings
43
Lifetime Open-Market Net
-$19.55M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PEPG | Director | — | $2.41 | — | $0 | 5 | 2026-06-22 |
| RLAY | Director | — | $19.75 | — | $0 | 2 | 2026-06-10 |
| Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Director | — | $21.53 | — | $0 | 5 | 2026-04-23 |
| TYRA | Director | — | $26.96 | — | $0 | 1 | 2026-04-20 |
| SGP | Director | — | $24.75 | — | $0 | 1 | 2026-02-09 |
| Blueprint Medicines Corp (BPMC) Delisted | Director | 8,742 | $129.46 | $1.13M | $0 | 5 | 2025-07-21 |
| Jade Biosciences, Inc. (AVTE) Delisted | Director | — | $93.80 | — | $0 | 4 | 2024-06-07 |
| ALBIREO PHARMA, INC. (ALBO) Delisted | Director | — | $44.15 | — | $0 | 2 | 2023-03-02 |
| ACCELERON PHARMA INC (XLRN) Delisted | CEO and President | 0 | $178.75 | $0 | -$19.55M | 14 | 2021-11-22 |
| Tempest Therapeutics, Inc. (MLND) Delisted | Director | — | $15.90 | — | $0 | 4 | 2020-06-23 |
Recent Filings · Page 3 of 5
43 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-06-23 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +2,600 | $0 | EDGAR |
| 2023-03-02 | ALBIREO PHARMA, INC. (ALBO) Delisted | Disp (D) | — | $0 | EDGAR |
| 2022-10-03 | PEPG | Grant (A) | — | $0 | EDGAR |
| 2022-08-10 | ALBIREO PHARMA, INC. (ALBO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-27 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +3,900 | $0 | EDGAR |
| 2021-11-22 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | −98,450 | $0 | EDGAR |
| 2021-07-02 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | — | -$9.18M | EDGAR |
| 2021-02-02 | ACCELERON PHARMA INC (XLRN) Delisted | Grant (A) | +16,662 | $0 | EDGAR |
| 2021-01-06 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | −7,536 | -$923.3K | EDGAR |
| 2020-07-06 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | — | -$3.07M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.